Chemokines and cytokines represent an emerging field of immunotherapy research. They
are responsible for the crosstalk and chemoattraction of immune cells and tumor cells. For …

The recent emergence of cancer immunotherapies initiated a significant shift in the clinical
management of metastatic melanoma. Prior to 2011, melanoma patients only had palliative …

The tumor microenvironment is highly heterogeneous. It is composed of a diverse array of
immune cells that are recruited continuously into lesions. They are guided into the tumor …

Melanoma is the leading cause of death among all skin cancers and its incidence continues
to rise rapidly worldwide in the past decades. The available treatment options for melanoma …

Malignant melanoma is on the rise. There have been recent advances in targeted agents
and immunotherapies that have improved the management and treatment of patients with …

Immunotherapy is a clinically validated treatment for many cancers to boost the immune
system against tumor growth and dissemination. Several strategies are used to harness …

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors
demonstrated their successful efficacy. Currently, the knowledge on the interaction between …

Recent advances in treating cutaneous melanoma have resulted in impressive patient
survival gains. Refinement of disease staging and accurate patient risk classification have …

8501 Background: Despite frequent induction of tumor antigen-specific T cells in melanoma
patients following vaccination, tumor regressions remain rare. This observation prompted …

Melanoma remains a leading cause of death among young adults. Evidence that melanoma
tumor cells are highly immunogenic and a better understanding of T-cell immune …